Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

A study of N-methyl-D-aspartate receptor gene (GRIN2B) variants as predictors of treatment-resistant major depression.

Psychopharmacology - 1 Feb 2014

Zhang Chen, Li Zezhi, Wu Zhiguo, Chen Jun, Wang Zuowei, Peng Daihui, Hong Wu, Yuan Chengmei, Wang Zhen, Yu Shunying, Xu Yifeng, Xu Lin, Xiao Zeping, Fang Yiru

Abstract excerpt

RATIONALE: In clinical practice, ketamine, an antagonist of the N-methyl-D-aspartate receptor (NMDAR), is used to alleviate depressive symptoms in patients with major depressive disorder (MDD), especially in those with treatment-resistant depression (TRD). Accordingly, the human gene coding for the 2B subunit of the NMDAR (GRIN2B) is considered a promising candidate gene for MDD susceptibility. OBJECTIVES: The...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Depressive Disorder, Major
Share to Gene Frequency

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Genetic Predisposition to Disease

Share to Genotyping Techniques

Share to Haplotypes

Share to Longitudinal Studies

Share to Polymorphism, Single Nucleotide

Share to Receptors, N-Methyl-D-Aspartate

Source

Identifiers

PMID: 24114429
DOI: 10.1007/s00213-013-3297-0

Genes

TRD

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 6 Sept 2026. Manifest publication-graph-cohort-2026-09-06.1.

Source receipt: pubmed, retrieved 6 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

A study of N-methyl-D-aspartate receptor gene (GRIN2B) variants as predictors of treatment-resistant major depression.PMID 24114429Read ↗

Effects of GRIN2B , GRIA1 , and BDNF Polymorphisms on the Therapeutic Action of Ketamine and Esketamine in Treatment-Resistant Depression Patients: Secondary Analysis From a Randomized Clinical Trial.Semantic proximity Read ↗

GRIN2B Gene Polymorphism in Chronic Ketamine Users.Semantic proximity Read ↗

Role of the Pharmacogenomics in the Treatment-Resistant Depression: A Literature ReviewSemantic proximity Read ↗

The role of GRIK4 gene in treatment-resistant depression.Semantic proximity Read ↗

Treatment response to low-dose ketamine infusion for treatment-resistant depression: A gene-based genome-wide association study.Semantic proximity Read ↗

Variations in the NMDA receptor subunit 2B gene (GRIN2B) and schizophrenia: a case-control study.Semantic proximity Read ↗

Common variants in GRIK4 and major depressive disorder: An association study in the Chinese Han population.Semantic proximity Read ↗

Influence of GRIA1, GRIA2 and GRIA4 polymorphisms on diagnosis and response to treatment in patients with major depressive disorder.Semantic proximity Read ↗

Association between NMDA gene polymorphism (rs4880213) and GRIN2B blood serum levels in thyroid pathology patients.Semantic proximity Read ↗

Evidence that the N-methyl-D-aspartate subunit 1 receptor gene (GRIN1) confers susceptibility to bipolar disorder.Semantic proximity Read ↗

The role of BDNF, NTRK2 gene and their interaction in development of treatment-resistant depression: data from multicenter, prospective, longitudinal clinic practice.Semantic proximity Read ↗

Association study between the NMDA receptor 2B subunit gene (GRIN2B) and schizophrenia: a HuGE review and meta-analysis.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.